ArticleJournal of substance abuse treatment2019
Fentanyl exposure among patients seeking opioid treatment.
Article in Journal of substance abuse treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Trial
- Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic.Journal of substance abuse treatment · 2021Trial
- A randomized, sham-controlled clinical trial to evaluate the NET Device™ for reducing withdrawal symptom severity during opioid discontinuation.Frontiers in psychiatry · 2025Article
- Post-discharge use of opioids, psychostimulants, and treatment medications following residential opioid discontinuation with NET Device™ monotherapy.Frontiers in psychiatry · 2025Article
- Fentanyl analog structure-activity relationships demonstrate determinants of diverging potencies for antinociception and respiratory depression.Pharmacology, biochemistry, and behavior · 2023Article
- Structurally diverse fentanyl analogs yield differential locomotor activities in mice.Pharmacology, biochemistry, and behavior · 2023Article
- A randomized, sham-controlled, quintuple-blinded trial to evaluate the NET device as an alternative to medication for promoting opioid abstinence.Contemporary clinical trials communications · 2022Article
- Respiratory depressant effects of fentanyl analogs are opioid receptor-mediated.Biochemical pharmacology · 2022Article
- Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder.Frontiers in pharmacology · 2022Article
- Fentanyl-related substances elicit antinociception and hyperlocomotion in mice via opioid receptors.Pharmacology, biochemistry, and behavior · 2021Article
- Use of an electronic pillbox to increase number of methadone take-home doses during the COVID-19 pandemic.Journal of substance abuse treatment · 2021Article
- Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone.The American journal on addictions · 2021Article
- Insights into the Neurobiology of Craving in Opioid Use Disorder.Current anesthesiology reports · 2020Article
- Protracted renal clearance of fentanyl in persons with opioid use disorder.Drug and alcohol dependence · 2020Article
- Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.BMJ (Clinical research ed.) · 2020Article
- Noradrenergic Mechanisms in Fentanyl-Mediated Rapid Death Explain Failure of Naloxone in the Opioid Crisis.The Journal of pharmacology and experimental therapeutics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
aimOverdoses attributed to the potent opioid agonist fentanyl have substantially increased in recent years. Despite these serious public health consequences, many opioid treatment providers do not currently include a fentanyl assay in their urine toxicology testing. As a result, extent of fentanyl exposure and related risks among individuals with opioid use disorder often remains unknown. We examined the prevalence of fentanyl exposure among patients seeking or enrolled in opioid agonist treatment.
methodsSix hundred urine specimens were collected from adults entering (n = 100) or enrolled in (n = 500) opioid agonist treatment and analyzed using the clinic's standard opioid panel, supplemented with a 100 ng/ml fentanyl assay.
resultsOf the 100 specimens collected from patients at treatment intake, 19 (19%) tested positive for fentanyl. Importantly, 17 (90%) of those fentanyl-positive specimens were also positive for heroin. Of the 500 collected from patients in treatment, 17 (3%) of specimens tested positive for fentanyl. Of those, 11 (92%) were also positive for heroin.
conclusionThese data illustrate a concerning degree of fentanyl exposure among patients seeking treatment and suggest that much of this exposure may have stemmed from fentanyl-containing heroin. Given the unprecedented recent surges in fentanyl-related overdoses, efforts to identify fentanyl exposure are critical. In particular, the point of treatment entry permits a rare systematic opportunity for medical and clinical staff to address fentanyl use and risks with incoming patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.